Core Viewpoint - The company, Jinfang Pharmaceutical-B (02595), announced the board's resolution to adopt the H-share option scheme and H-share incentive plan on November 24, 2025, aimed at providing qualified individuals with opportunities to gain equity interests in the company and to enhance the overall value for shareholders [1] Group 1 - The H-share option scheme and H-share incentive plan are collectively referred to as the "Share Scheme" [1] - The Share Scheme is designed to encourage qualified individuals, including employee participants, service providers, and related entity participants, to work towards enhancing the company's value and that of its shares [1] - The Share Scheme is expected to retain, incentivize, and reward qualified individuals, providing flexible means of compensation, remuneration, and/or benefits [1]
劲方医药-B(02595)建议采纳H股购股权计划及H股股份激励计划